TIA
MCID: TRN015
MIFTS: 63

Transient Cerebral Ischemia (TIA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Transient Cerebral Ischemia

MalaCards integrated aliases for Transient Cerebral Ischemia:

Name: Transient Cerebral Ischemia 12 54 15 71
Transient Ischemic Attack 12 53 54 6 42 17 71
Transient Ischemic Attacks 12 15
Tia - Transient Ischaemic Attack 12
Transient Cerebral Ischaemia 12
Ischemic Attack, Transient 43
Tia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:224
MeSH 43 D002546
NCIt 49 C50781
SNOMED-CT 67 266257000
ICD10 32 G45.9
UMLS 71 C0007787 C0917805

Summaries for Transient Cerebral Ischemia

MedlinePlus : 42 A transient ischemic attack (TIA) is a stroke that lasts only a few minutes. It happens when the blood supply to part of the brain is briefly blocked. Symptoms of a TIA are like other stroke symptoms, but do not last as long. They happen suddenly, and include Numbness or weakness, especially on one side of the body Confusion or trouble speaking or understanding speech Trouble seeing in one or both eyes Difficulty walking Dizziness Loss of balance or coordination Most symptoms of a TIA disappear within an hour, although they may last for up to 24 hours. Because you cannot tell if these symptoms are from a TIA or a stroke, you should go to the hospital right away. TIAs are often a warning sign for future strokes. Taking medicine, such as blood thinners, may reduce your risk of a stroke. Your doctor might also recommend surgery. You can also help lower your risk by having a healthy lifestyle. This includes not smoking, not drinking too much, eating a healthy diet, and exercising. It is also important to control other health problems, such as high blood pressure and cholesterol. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Transient Cerebral Ischemia, also known as transient ischemic attack, is related to ischemia and amnestic disorder, and has symptoms including seizures, edema and tremor. An important gene associated with Transient Cerebral Ischemia is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are Neuroscience and G-protein signaling Ras family GTPases in kinase cascades (scheme). The drugs Aspirin and Irbesartan have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A brain ischemia that is characterized by ischemia of brief duration and without resultant tissue death.

NINDS : 53 A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.

Wikipedia : 74 A transient ischemic attack (TIA), commonly known as a mini-stroke, is a brief episode of neurological... more...

Related Diseases for Transient Cerebral Ischemia

Diseases related to Transient Cerebral Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 503, show less)
# Related Disease Score Top Affiliating Genes
1 ischemia 31.7 MAP2 HSPA4 HSPA1A CASP3
2 amnestic disorder 31.0 MAPT DRD1 ACHE
3 retinal ischemia 30.8 IL1B HSPA4 CASP3
4 peripheral nervous system disease 30.7 IL1B CCL2 CASP3 ACHE
5 cytomegalovirus infection 30.6 IL1B CCL2 CASP3
6 carotid artery occlusion 30.3 MAP2 IL1B HSPA1A CASP3 APOH
7 anxiety 30.2 SLC1A1 IL1B GRIN2A ACHE
8 binswanger's disease 30.1 NOTCH3 MAPT ACHE
9 agraphia 29.9 MAPT ACHE
10 dementia 29.7 NOTCH3 MAPT MAP2 IL1B ACHE
11 encephalomalacia 29.7 MTHFR IL1B CASP3
12 spinal cord infarction 29.5 MTHFR APOH
13 retinal artery occlusion 29.4 MTHFR CCL2 APOH
14 homocysteinemia 29.4 MTHFR CCL2 APOH
15 vascular disease 29.3 MTHFR HSPA4 CCL2 CASP3 APOH
16 intracranial hypertension 29.3 MTHFR IL1B APOH
17 retinal vein occlusion 29.3 MTHFR IL1B CCL2 APOH
18 placenta disease 29.2 MTHFR IL1B APOH
19 migraine with or without aura 1 29.0 NOTCH3 MTHFR IL1B DRD1 APOH
20 migraine without aura 29.0 NOTCH3 MTHFR DRD1 CCR2 CCL2
21 vascular dementia 28.9 NOTCH3 MTHFR MAPT IL1B GRIN2A CASP3
22 cerebrovascular disease 28.9 NOTCH3 MTHFR MAPT APOH ACHE
23 thrombocytopenia 28.7 MTHFR IL1B CCL2 CASP3 APOH
24 myocardial infarction 28.6 MTHFR IL1B HSPA4 CCR2 CCL2 CASP3
25 stroke, ischemic 27.9 NOTCH3 MTHFR MAPT MAP2 IL1B HSPA4
26 mini stroke 11.9
27 paresthesia 11.7
28 pulmonary arteriovenous fistulas 11.7
29 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.7
30 essential thrombocythemia 11.7
31 moyamoya disease 1 11.7
32 carotid artery disease 11.7
33 sneddon syndrome 11.5
34 moyamoya disease 2 11.5
35 moyamoya disease 6 with or without achalasia 11.5
36 buerger disease 11.4
37 telangiectasia, hereditary hemorrhagic, type 4 11.4
38 moyamoya disease 5 11.4
39 aganglionosis, total intestinal 11.3
40 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 11.2
41 cerebral artery occlusion 10.8
42 palladium allergic contact dermatitis 10.6 IL1B CCL2
43 carbuncle 10.5 IL1B CASP3 ACHE
44 ectodermal dysplasia 1, hypohidrotic, x-linked 10.5 IL1B CCL2 CASP3
45 simultanagnosia 10.5 MAPT ACHE
46 congenital cytomegalovirus 10.5 IL1B CCL2
47 yellow fever 10.5 IL1B CCL2 CASP3
48 atrial fibrillation 10.5
49 pneumoconiosis 10.5 IL1B CCL2 CASP3
50 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 10.4 IL1B CCL2 CASP3
51 neuritis 10.4 MAPT IL1B CCL2
52 alcoholic hepatitis 10.4 IL1B CCL2 CASP3
53 leishmaniasis 10.4 ODC1 IL1B HSPA4 CCL2
54 brain edema 10.4
55 specific developmental disorder 10.4 MAPT IL1B GRIN2A DRD1
56 parasitic protozoa infectious disease 10.4 IL1B HSPA4 CCL2
57 stachybotrys chartarum 10.4 IL1B CCL2
58 obsessive-compulsive disorder 10.3 SLC1A1 IL1B GRIN2A DRD1 CCL2
59 vertebrobasilar insufficiency 10.3
60 thrombocytosis 10.3
61 sleep apnea 10.3
62 disease of mental health 10.3 MAPT IL1B GRIN2A DRD1 ACHE
63 alzheimer disease 10 10.3 MAPT ACHE
64 hyperglycemia 10.3
65 ataxia and polyneuropathy, adult-onset 10.3
66 papilledema 10.3
67 intermediate coronary syndrome 10.3
68 sickle cell disease 10.3
69 nominal aphasia 10.2 MAPT ACHE
70 meningitis 10.2
71 thrombophilia due to thrombin defect 10.2
72 peripheral vascular disease 10.2
73 pure autonomic failure 10.2
74 headache 10.2
75 cardiac arrest 10.2
76 alcohol use disorder 10.2
77 huntington disease 10.2 MAPT HSPA4 GRIN2A DRD1 CASP3 ACHE
78 apnea, obstructive sleep 10.2
79 hemiplegia 10.2
80 heart septal defect 10.2
81 brain stem infarction 10.2
82 pathologic nystagmus 10.2
83 temporal arteritis 10.2 IL1B CCL2 APOH
84 occlusion precerebral artery 10.2 MAP2 IL1B CASP3
85 cerebral amyloid angiopathy, cst3-related 10.2
86 specific language disorder 10.2
87 48,xyyy 10.2
88 atrial standstill 1 10.1
89 endocarditis 10.1
90 brucellosis 10.1
91 hereditary hemorrhagic telangiectasia 10.1
92 telangiectasis 10.1
93 dilated cardiomyopathy 10.1
94 atrial heart septal defect 10.1
95 sleep disorder 10.1
96 chronic kidney disease 10.1
97 neuropathy 10.1
98 eagle syndrome 10.1
99 fainting 10.1
100 tremor 10.1
101 fabry disease 10.1
102 coronary heart disease 1 10.1
103 lipid metabolism disorder 10.1
104 meningioma, radiation-induced 10.1
105 meningioma, familial 10.1
106 spinal meningioma 10.1
107 visual epilepsy 10.1
108 secretory meningioma 10.1
109 lymphoplasmacyte-rich meningioma 10.1
110 seizure disorder 10.1
111 mesenteric vascular occlusion 10.1 ODC1 MTHFR
112 autoimmune disease of musculoskeletal system 10.1 IL1B CCL2 APOH
113 scrapie 10.0 MAPT MAP2 ACHE
114 asplenia, isolated congenital 10.0
115 angina pectoris 10.0
116 peripheral artery disease 10.0
117 migraine with aura 10.0
118 post-traumatic stress disorder 10.0
119 thrombophilia 10.0
120 acute stress disorder 10.0
121 herpes zoster 10.0
122 47,xyy 10.0
123 syncope 10.0
124 autoimmune disease 10.0
125 rheumatoid arthritis 10.0
126 sarcoidosis 1 10.0
127 takayasu arteritis 10.0
128 phace association 10.0
129 acute promyelocytic leukemia 10.0
130 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.0
131 infective endocarditis 10.0
132 stuttering 10.0
133 cryptococcal meningitis 10.0
134 meningoencephalitis 10.0
135 nephrotic syndrome 10.0
136 hypertrophic cardiomyopathy 10.0
137 subclavian steal syndrome 10.0
138 acute cystitis 10.0
139 basilar artery occlusion 10.0
140 polyneuropathy 10.0
141 mental depression 10.0
142 mitral valve stenosis 10.0
143 hemangioma 10.0
144 sagittal sinus thrombosis 10.0
145 protein c deficiency 10.0
146 myopathy 10.0
147 coronary stenosis 10.0
148 kidney disease 10.0
149 aortic valve insufficiency 10.0
150 hemolytic anemia 10.0
151 homocystinuria 10.0
152 scotoma 10.0
153 hemophilia 10.0
154 pulmonary arteriovenous malformation 10.0
155 thunderclap headache 10.0
156 autonomic dysfunction 10.0
157 superficial siderosis 10.0
158 chronic enteropathy associated with slco2a1 gene 10.0
159 pik3ca-related overgrowth syndrome 10.0
160 demyelinating disease 10.0 MAPT MAP2 IL1B CCL2
161 optic atrophy 1 10.0
162 3-methylglutaconic aciduria, type iii 10.0
163 frontotemporal dementia 10.0
164 orthostatic intolerance 10.0
165 lactic acidosis 10.0
166 hypoglycemia 10.0
167 amaurosis fugax 10.0
168 aneurysm 10.0
169 brain injury 10.0
170 gastroschisis 10.0 MTHFR IL1B ACHE
171 nephrosclerosis 10.0 MTHFR CCL2 CASP3
172 hypertriglyceridemia, familial 10.0
173 schistosoma mansoni infection, susceptibility/ 10.0
174 paragonimiasis 10.0
175 arteriovenous malformation 10.0
176 clonorchiasis 10.0
177 schistosomiasis 10.0
178 echinococcosis 10.0
179 glioblastoma multiforme 10.0
180 purpura 10.0
181 heart valve disease 10.0
182 movement disease 10.0
183 neurotic disorder 10.0
184 congestive heart failure 10.0
185 influenza 10.0
186 subacute delirium 10.0
187 fascioliasis 10.0
188 carotid artery dissection 10.0
189 depression 10.0
190 atrial fibrillation and stroke 10.0
191 cerebral atrophy 10.0
192 myoclonus 10.0
193 monocytic leukemia 9.9 IL1B CCL2 CASP3
194 pick disease of brain 9.9 MAPT MAP2 HSPA4 CASP3 ACHE
195 prion disease 9.9 MAPT MAP2 IL1B
196 mucositis 9.9 MTHFR IL1B CASP3
197 retinal vascular disease 9.9 MTHFR IL1B CCL2 CASP3
198 abducens palsy 9.9
199 alzheimer disease 9.9
200 progressive familial heart block, type ia 9.9
201 carpal tunnel syndrome 9.9
202 multiple sclerosis 9.9
203 esophageal cancer 9.9
204 spondyloepiphyseal dysplasia with congenital joint dislocations 9.9
205 systemic lupus erythematosus 9.9
206 neural tube defects 9.9
207 spondylosis, cervical 9.9
208 strabismus 9.9
209 varicose veins 9.9
210 acrocallosal syndrome 9.9
211 afibrinogenemia, congenital 9.9
212 chondrosarcoma 9.9
213 hemolytic uremic syndrome, atypical 1 9.9
214 lymphoma, hodgkin, classic 9.9
215 intracranial hypertension, idiopathic 9.9
216 pulmonary hypoplasia, primary 9.9
217 danon disease 9.9
218 sarcoma, synovial 9.9
219 moyamoya disease 4 with short stature, hypergonadotropic hypogonadism, and facial dysmorphism 9.9
220 charcot-marie-tooth disease, x-linked dominant, 1 9.9
221 hemophilia a 9.9
222 hemophilia b 9.9
223 mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 9.9
224 progressive familial heart block, type ib 9.9
225 cerebral amyloid angiopathy, app-related 9.9
226 aneurysmal bone cysts 9.9
227 pulmonary disease, chronic obstructive 9.9
228 major depressive disorder 9.9
229 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
230 intraocular pressure quantitative trait locus 9.9
231 microvascular complications of diabetes 5 9.9
232 beta-thalassemia 9.9
233 muscle hypertrophy 9.9
234 peripartum cardiomyopathy 9.9
235 membranous nephropathy 9.9
236 atrial fibrillation, familial, 15 9.9
237 striatal degeneration, autosomal dominant 2 9.9
238 aspiration pneumonia 9.9
239 chronic venous insufficiency 9.9
240 fibroma 9.9
241 amusia 9.9
242 colitis 9.9
243 ptosis 9.9
244 left ventricular noncompaction 9.9
245 cysticercosis 9.9
246 venous insufficiency 9.9
247 osteomyelitis 9.9
248 aortic atherosclerosis 9.9
249 thalassemia 9.9
250 left bundle branch hemiblock 9.9
251 pre-eclampsia 9.9
252 sarcoma 9.9
253 respiratory failure 9.9
254 primary hyperparathyroidism 9.9
255 orbital cellulitis 9.9
256 alternating exotropia 9.9
257 exotropia 9.9
258 hemopericardium 9.9
259 mitral valve insufficiency 9.9
260 autonomic neuropathy 9.9
261 hypertensive retinopathy 9.9
262 presbyopia 9.9
263 pericardial effusion 9.9
264 mononeuropathy 9.9
265 allergic hypersensitivity disease 9.9
266 leukemia 9.9
267 hemolytic-uremic syndrome 9.9
268 locked-in syndrome 9.9
269 quadriplegia 9.9
270 branch retinal artery occlusion 9.9
271 focal segmental glomerulosclerosis 9.9
272 right bundle branch block 9.9
273 hyperparathyroidism 9.9
274 poems syndrome 9.9
275 generalized anxiety disorder 9.9
276 cholesterol embolism 9.9
277 angioedema 9.9
278 cystitis 9.9
279 calcinosis 9.9
280 cerebral palsy 9.9
281 myeloproliferative neoplasm 9.9
282 central retinal vein occlusion 9.9
283 tic disorder 9.9
284 hemoglobinopathy 9.9
285 glomerulonephritis 9.9
286 anuria 9.9
287 substance abuse 9.9
288 acute kidney failure 9.9
289 cellulitis 9.9
290 cerebral arterial disease 9.9
291 choriocarcinoma 9.9
292 plasmacytoma 9.9
293 pituitary adenoma 9.9
294 spindle cell sarcoma 9.9
295 radiculopathy 9.9
296 uremia 9.9
297 prosopagnosia 9.9
298 essential tremor 9.9
299 liver cirrhosis 9.9
300 aortic disease 9.9
301 dystonia 9.9
302 silent myocardial infarction 9.9
303 paraplegia 9.9
304 lymphopenia 9.9
305 severe combined immunodeficiency 9.9
306 mitochondrial myopathy 9.9
307 mitochondrial metabolism disease 9.9
308 thyroiditis 9.9
309 peptic ulcer disease 9.9
310 petroclival meningioma 9.9
311 end stage renal disease 9.9
312 cocaine abuse 9.9
313 osteochondrosis 9.9
314 mediastinitis 9.9
315 arthritis 9.9
316 collagen disease 9.9
317 ulcerative colitis 9.9
318 chickenpox 9.9
319 speech disorder 9.9
320 erythromelalgia 9.9
321 mechanical strabismus 9.9
322 cannabis abuse 9.9
323 mitochondrial disorders 9.9
324 acquired hemophilia 9.9
325 acquired hemophilia a 9.9
326 carotidynia 9.9
327 cor triatriatum 9.9
328 coronary artery aneurysm 9.9
329 germ cells tumors 9.9
330 herpes zoster ophthalmicus 9.9
331 internal carotid agenesis 9.9
332 mast cell activation syndrome 9.9
333 primary angiitis of the central nervous system 9.9
334 pseudobulbar affect 9.9
335 st anthony's fire 9.9
336 spinal cord injury 9.9
337 rare cardiac tumor 9.9
338 dural sinus malformation 9.9
339 thrombotic microangiopathy 9.9
340 cardiac arrhythmia 9.9
341 fibromuscular dysplasia 9.9
342 attention deficit-hyperactivity disorder 9.9
343 hypercholesterolemia, familial, 1 9.9
344 hyperlipoproteinemia, type iv 9.9
345 neutrophil migration 9.9
346 retinoblastoma 9.9
347 proteasome-associated autoinflammatory syndrome 1 9.9
348 yemenite deaf-blind hypopigmentation syndrome 9.9
349 mitral valve prolapse 2 9.9
350 aortic valve disease 2 9.9
351 alacrima, achalasia, and mental retardation syndrome 9.9
352 thrombocytopenia 6 9.9
353 helix syndrome 9.9
354 chlamydia pneumonia 9.9
355 fetal alcohol syndrome 9.9
356 fetal alcohol spectrum disorder 9.9
357 limb ischemia 9.9
358 aphasia 9.9
359 brain meningioma 9.9
360 porencephaly 9.9
361 thrombosis 9.9
362 benign teratoma 9.9
363 glucose intolerance 9.9
364 intracranial aneurysm 9.9
365 chlamydia 9.9
366 retinal microaneurysm 9.9
367 vertebral artery occlusion 9.9
368 tetanus 9.9
369 pulmonary edema 9.9
370 hypertensive heart disease 9.9
371 cerebral atherosclerosis 9.9
372 carotid stenosis 9.9
373 transient global amnesia 9.9
374 patent foramen ovale 9.9
375 hypothyroidism 9.9
376 pneumothorax 9.9
377 focal epilepsy 9.9
378 arteriosclerosis 9.9
379 protein s deficiency 9.9
380 cystic teratoma 9.9
381 cockayne syndrome 9.9
382 antiphospholipid syndrome 9.9
383 middle cerebral artery infarction 9.9
384 anovulation 9.9
385 familial retinoblastoma 9.9
386 mature teratoma 9.9
387 adenoma 9.9
388 b-cell lymphoma 9.9
389 vasculitis 9.9
390 acute mountain sickness 9.9
391 cerebellar degeneration 9.9
392 cerebral aneurysms 9.9
393 cerebral arteriosclerosis 9.9
394 hypoxia 9.9
395 interatrial communication 9.9
396 atrial septal aneurysm 9.9
397 aortic aneurysm, familial abdominal, 1 9.8
398 alcohol dependence 9.8
399 arteries, anomalies of 9.8
400 atherosclerosis susceptibility 9.8
401 aortic valve disease 1 9.8
402 renal cell carcinoma, nonpapillary 9.8
403 polykaryocytosis inducer 9.8
404 sturge-weber syndrome 9.8
405 thrombophilia due to activated protein c resistance 9.8
406 argininosuccinic aciduria 9.8
407 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.8
408 hydrocephalus, congenital, 1 9.8
409 netherton syndrome 9.8
410 ocular motor apraxia 9.8
411 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 9.8
412 body mass index quantitative trait locus 1 9.8
413 creatinine clearance quantitative trait locus 9.8
414 resting heart rate, variation in 9.8
415 aspirin resistance 9.8
416 colorectal cancer 2 9.8
417 diabetes mellitus, ketosis-prone 9.8
418 cyanosis, transient neonatal 9.8
419 hyperlipoproteinemia, type iii 9.8
420 lipoprotein quantitative trait locus 9.8
421 speech and communication disorders 9.8
422 deficiency anemia 9.8
423 restless legs syndrome 9.8
424 meningovascular neurosyphilis 9.8
425 anosognosia 9.8
426 covid-19 9.8
427 middle east respiratory syndrome 9.8
428 aortic dissection 9.8
429 asymptomatic neurosyphilis 9.8
430 viral meningitis 9.8
431 siderosis 9.8
432 thrombotic thrombocytopenic purpura 9.8
433 filariasis 9.8
434 gastric ulcer 9.8
435 hydrocephalus 9.8
436 disseminated intravascular coagulation 9.8
437 adult respiratory distress syndrome 9.8
438 heart disease 9.8
439 lyme disease 9.8
440 iron deficiency anemia 9.8
441 pica disease 9.8
442 bell's palsy 9.8
443 sick sinus syndrome 9.8
444 facial paralysis 9.8
445 iritis 9.8
446 normal pressure hydrocephalus 9.8
447 hepatitis 9.8
448 spondylosis 9.8
449 generalized atherosclerosis 9.8
450 iron metabolism disease 9.8
451 astrocytoma 9.8
452 oligodendroglioma 9.8
453 mood disorder 9.8
454 aortic aneurysm 9.8
455 intermittent claudication 9.8
456 tricuspid valve insufficiency 9.8
457 syphilis 9.8
458 systemic scleroderma 9.8
459 intracranial thrombosis 9.8
460 intracranial embolism 9.8
461 dysgraphia 9.8
462 angiokeratoma 9.8
463 trachea carcinoma 9.8
464 mitral valve disease 9.8
465 periodontitis 9.8
466 cataract 9.8
467 polycythemia 9.8
468 herpes simplex 9.8
469 lupus erythematosus 9.8
470 amebiasis 9.8
471 acute myocardial infarction 9.8
472 pulmonary embolism 9.8
473 encephalitis 9.8
474 hypereosinophilic syndrome 9.8
475 bow hunter's stroke 9.8
476 light chain deposition disease 9.8
477 neurosyphilis 9.8
478 weber syndrome 9.8
479 clopidogrel resistance 9.8
480 angiomatosis 9.8
481 cerebral hypoxia 9.8
482 dysphagia 9.8
483 encephalopathy 9.8
484 spasticity 9.8
485 rapidly involuting congenital hemangioma 9.8
486 low-grade astrocytoma 9.8
487 malaria 9.8 ODC1 IL1B HSPA4 CCL2 CASP3 APOH
488 psychotic disorder 9.8 SLC1A1 MTHFR GRIN2A DRD1 ACHE
489 sudden sensorineural hearing loss 9.8 MTHFR APOH
490 parkinson disease, late-onset 9.8 MAPT MAP2 HSPA4 DRD1 CASP3 ACHE
491 neuroblastoma 9.7 ODC1 MAPT MAP2 IL1B HSPA4 CASP3
492 catastrophic antiphospholipid syndrome 9.7 MTHFR APOH
493 retinal vascular occlusion 9.7 MTHFR CCL2 APOH
494 livedoid vasculitis 9.7 MTHFR APOH
495 toxic encephalopathy 9.6 MAPT MAP2 IL1B HSPA4 GRIN2A CCL2
496 cerebral sinovenous thrombosis 9.6 MTHFR APOH
497 pregnancy loss, recurrent 1 9.6 MTHFR APOH
498 behcet syndrome 9.6 MTHFR IL1B CCL2 APOH
499 hypertension, essential 9.5 MTHFR IL1B HSPA4 HSPA1A DRD1 CCR2
500 diabetes mellitus, noninsulin-dependent 9.5 PTK2B MTHFR IL1B HSPA4 HSPA1A CCL2
501 autism 9.4 SLC1A1 MTHFR MAPT IL1B GRIN2A DRD1
502 bipolar disorder 9.2 SLC1A1 MTHFR MAPT MAP2 IL1B GRIN2A
503 schizophrenia 8.8 SLC1A1 MTHFR MAPT MAP2 KMO IL1B

Comorbidity relations with Transient Cerebral Ischemia via Phenotypic Disease Network (PDN): (showing 86, show less)


Active Peptic Ulcer Disease Acute Cystitis
Acute Myocardial Infarction Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Atrioventricular Block
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Maxillary Sinusitis
Communicating Hydrocephalus Conjunctivitis
Conversion Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Facial Paralysis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hyperlipoproteinemia, Type Iv
Hypertension, Essential Hypertensive Encephalopathy
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Inner Ear Disease
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Kidney Disease Labyrinthitis
Left Bundle Branch Hemiblock Macular Degeneration, Age-Related, 1
Major Depressive Disorder Malignant Essential Hypertension
Meniere Disease Microvascular Complications of Diabetes 1
Migraine with Aura Migraine with or Without Aura 1
Mitral Valve Disease Mitral Valve Stenosis
Mononeuropathy of the Median Nerve, Mild Neurogenic Bladder
Obstructive Hydrocephalus Osteoarthritis
Osteoporosis Parkinson Disease, Late-Onset
Peripheral Vascular Disease Pernicious Anemia
Postinflammatory Pulmonary Fibrosis Primary Polycythemia
Progressive Familial Heart Block, Type Ia Protein-Energy Malnutrition
Pseudobulbar Palsy Pulmonary Valve Disease
Renal Artery Atheroma Rheumatic Heart Disease
Right Bundle Branch Block Schizophreniform Disorder
Sinoatrial Node Disease Spastic Hemiplegia
Status Epilepticus Subclavian Steal Syndrome
Swallowing Disorders Temporal Arteritis
Transient Global Amnesia Transient Retinal Arterial Occlusion
Tricuspid Valve Disease Vertebral Artery Insufficiency
Vertigo, Benign Recurrent Viral Labyrinthitis

Graphical network of the top 20 diseases related to Transient Cerebral Ischemia:



Diseases related to Transient Cerebral Ischemia

Symptoms & Phenotypes for Transient Cerebral Ischemia

UMLS symptoms related to Transient Cerebral Ischemia:


seizures, edema, tremor, chest pain, back pain, angina pectoris, headache, syncope, amaurosis fugax, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, transient ischemic attacks, differing symptoms, transient ischemic attacks, stereotypic symptoms

MGI Mouse Phenotypes related to Transient Cerebral Ischemia:

45 (showing 3, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 ACHE CASP3 CCR2 DRD1 GRIN2A HSPA4
2 homeostasis/metabolism MP:0005376 9.77 ACHE APOH CASP3 CCR2 DRD1 IL1B
3 nervous system MP:0003631 9.4 ACHE CASP3 CCR2 DRD1 GRIN2A HSPA4

Drugs & Therapeutics for Transient Cerebral Ischemia

Drugs for Transient Cerebral Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 315, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
5
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
6
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
10
Nicotine Approved Phase 4 54-11-5 942 89594
11
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
12
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
13
Metformin Approved Phase 4 657-24-9 14219 4091
14
Amlodipine Approved Phase 4 88150-42-9 2162
15
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
16
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
17
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
18
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
19
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
20
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
21
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
22
Simvastatin Approved Phase 4 79902-63-9 54454
23
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
24
Losartan Approved Phase 4 114798-26-4 3961
25
Pravastatin Approved Phase 4 81093-37-0 54687
26
Apixaban Approved Phase 4 503612-47-3 10182969
27
Atorvastatin Approved Phase 4 134523-00-5 60823
28
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
29
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
30
Ethanol Approved Phase 4 64-17-5 702
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
33
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
34
Candesartan Experimental Phase 4 139481-59-7 2541
35
Dabigatran Investigational Phase 4 211914-51-1
36 Fibrinolytic Agents Phase 4
37 Analgesics, Non-Narcotic Phase 4
38 Analgesics Phase 4
39 Platelet Aggregation Inhibitors Phase 4
40 Cyclooxygenase Inhibitors Phase 4
41 Antirheumatic Agents Phase 4
42 Antipyretics Phase 4
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4
44 Radiation-Protective Agents Phase 4
45 Phosphodiesterase 5 Inhibitors Phase 4
46 Vardenafil Dihydrochloride Phase 4
47 Citrate Phase 4
48 Sildenafil Citrate Phase 4 171599-83-0
49 Trace Elements Phase 4
50 Vitamins Phase 4
51 Vitamin B Complex Phase 4
52 Nutrients Phase 4
53 Folate Phase 4
54 Micronutrients Phase 4
55 Vitamin B9 Phase 4
56 Hypoglycemic Agents Phase 4
57 Phosphodiesterase Inhibitors Phase 4
58 calcium heparin Phase 4
59 Psychotropic Drugs Phase 4
60 Dopamine Agents Phase 4
61 Cytochrome P-450 Enzyme Inhibitors Phase 4
62 Antidepressive Agents Phase 4
63 Cholinergic Agents Phase 4
64 Nicotinic Agonists Phase 4
65
Olmesartan medoxomil Phase 4 144689-63-4 130881
66 Nicotinic Acids Phase 4
67 Vitamin B3 Phase 4
68 Angiotensin Receptor Antagonists Phase 4
69 diuretics Phase 4
70 calcium channel blockers Phase 4
71 Angiotensin II Type 1 Receptor Blockers Phase 4
72 Angiotensinogen Phase 4
73 Giapreza Phase 4
74 Adrenergic alpha-Antagonists Phase 4
75 Diuretics, Potassium Sparing Phase 4
76 Sodium Chloride Symporter Inhibitors Phase 4
77 Mineralocorticoids Phase 4
78 Mineralocorticoid Receptor Antagonists Phase 4
79 Vaccines Phase 4
80 Neurotransmitter Agents Phase 4
81 Antihypertensive Agents Phase 4
82 Anticoagulants Phase 4
83 Protective Agents Phase 4
84 Adrenergic Agents Phase 4
85 Cardiotonic Agents Phase 4
86 Antithrombins Phase 4
87 Antithrombin III Phase 4
88 Serine Proteinase Inhibitors Phase 4
89
protease inhibitors Phase 4
90 HIV Protease Inhibitors Phase 4
91 Lipid Regulating Agents Phase 4
92 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
93 Anticholesteremic Agents Phase 4
94 Hypolipidemic Agents Phase 4
95 Antimetabolites Phase 4
96 Calcium, Dietary Phase 4
97 Rosuvastatin Calcium Phase 4 147098-20-2
98 Coagulants Phase 4
99 Adrenergic beta-Antagonists Phase 4
100 Adrenergic beta-1 Receptor Antagonists Phase 4
101 Angiotensin-Converting Enzyme Inhibitors Phase 4
102 Adrenergic Antagonists Phase 4
103 Sympatholytics Phase 4
104 Anti-Arrhythmia Agents Phase 4
105
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
106
Calcium Nutraceutical Phase 4 7440-70-2 271
107
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
108
Phenprocoumon Approved, Investigational Phase 3 435-97-2 54680692 9908
109 fluindione Approved, Investigational Phase 3 957-56-2
110
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
111
4-Aminopyridine Approved Phase 2, Phase 3 504-24-5 1727
112
Furosemide Approved, Vet_approved Phase 3 54-31-9 3440
113
Procainamide Approved Phase 3 51-06-9 4913
114
Diltiazem Approved, Investigational Phase 3 42399-41-7 39186
115
Amiodarone Approved, Investigational Phase 3 1951-25-3 2157
116
Sotalol Approved Phase 3 3930-20-9, 959-24-0 5253
117
Digoxin Approved Phase 3 20830-75-5 30322 2724385
118
Verapamil Approved Phase 3 52-53-9 2520
119
Disopyramide Approved Phase 3 3737-09-5 3114
120
Quinidine Approved, Investigational Phase 3 56-54-2 441074
121
Propafenone Approved Phase 3 54063-53-5